PE20210668A1 - Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales - Google Patents

Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales

Info

Publication number
PE20210668A1
PE20210668A1 PE2020000354A PE2020000354A PE20210668A1 PE 20210668 A1 PE20210668 A1 PE 20210668A1 PE 2020000354 A PE2020000354 A PE 2020000354A PE 2020000354 A PE2020000354 A PE 2020000354A PE 20210668 A1 PE20210668 A1 PE 20210668A1
Authority
PE
Peru
Prior art keywords
carba
antivirals
fluorine
refers
nucleosid
Prior art date
Application number
PE2020000354A
Other languages
English (en)
Inventor
Aesop Cho
Choung U Kim
Samuel E Metobo
Adrian S Ray
Jie Xu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PE20210668A1 publication Critical patent/PE20210668A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • G—PHYSICS
    • G03—PHOTOGRAPHY; CINEMATOGRAPHY; ANALOGOUS TECHNIQUES USING WAVES OTHER THAN OPTICAL WAVES; ELECTROGRAPHY; HOLOGRAPHY
    • G03C—PHOTOSENSITIVE MATERIALS FOR PHOTOGRAPHIC PURPOSES; PHOTOGRAPHIC PROCESSES, e.g. CINE, X-RAY, COLOUR, STEREO-PHOTOGRAPHIC PROCESSES; AUXILIARY PROCESSES IN PHOTOGRAPHY
    • G03C7/00—Multicolour photographic processes or agents therefor; Regeneration of such processing agents; Photosensitive materials for multicolour processes
    • G03C7/30—Colour processes using colour-coupling substances; Materials therefor; Preparing or processing such materials
    • G03C7/32—Colour coupling substances
    • G03C7/36—Couplers containing compounds with active methylene groups
    • G03C7/38—Couplers containing compounds with active methylene groups in rings
    • G03C7/381—Heterocyclic compounds
    • G03C7/382—Heterocyclic compounds with two heterocyclic rings
    • G03C7/3825—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms
    • G03C7/3835—Heterocyclic compounds with two heterocyclic rings the nuclei containing only nitrogen as hetero atoms four nitrogen atoms

Abstract

Referido a compuestos analogos de carba-nucleosidos sustituidos con 2'-fluoro del grupo A, o una sal farmaceuticamente aceptable del mismo. Estos compuestos antivirales son utiles en el tratamiento de infecciones por virus Flaviviridae; tambien se refiere a procedimientos para la preparacion de dichos compuestos y sus profarmacos; a una composicion farmaceutica que comprende este compuesto ademas de al menos un agente terapeutico adicional, y mas particularmente a inhibidores de la ARN polimerasa dependiente de ARN del virus de la hepatitis C.
PE2020000354A 2009-09-21 2010-09-20 Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales PE20210668A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24429709P 2009-09-21 2009-09-21
PCT/US2010/049471 WO2011035231A1 (en) 2009-09-21 2010-09-20 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
PE20210668A1 true PE20210668A1 (es) 2021-04-05

Family

ID=43031517

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2020000354A PE20210668A1 (es) 2009-09-21 2010-09-20 Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
PE2012000359A PE20120995A1 (es) 2009-09-21 2010-09-20 Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
PE2016000070A PE20160217A1 (es) 2009-09-21 2010-09-20 Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2012000359A PE20120995A1 (es) 2009-09-21 2010-09-20 Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
PE2016000070A PE20160217A1 (es) 2009-09-21 2010-09-20 Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales

Country Status (32)

Country Link
EP (2) EP2480552B1 (es)
JP (3) JP5795766B2 (es)
KR (2) KR101818779B1 (es)
CN (1) CN102596958A (es)
AP (1) AP2012006189A0 (es)
AU (4) AU2010295373B2 (es)
BR (2) BR122021021135B1 (es)
CA (1) CA2773772C (es)
CL (1) CL2012000707A1 (es)
CR (2) CR20190103A (es)
CY (1) CY1118605T1 (es)
DK (1) DK2480552T3 (es)
EA (1) EA201200525A1 (es)
EC (1) ECSP12011817A (es)
ES (2) ES2614651T3 (es)
HR (1) HRP20170197T1 (es)
HU (1) HUE032252T2 (es)
IL (2) IL218599A (es)
LT (1) LT2480552T (es)
ME (1) ME02656B (es)
MX (1) MX352646B (es)
NZ (1) NZ599402A (es)
PE (3) PE20210668A1 (es)
PL (1) PL2480552T3 (es)
PT (1) PT2480552T (es)
RS (1) RS55699B1 (es)
SG (1) SG179194A1 (es)
SI (1) SI2480552T1 (es)
SM (1) SMT201700091B (es)
UA (1) UA110466C2 (es)
WO (1) WO2011035231A1 (es)
ZA (1) ZA201202175B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008264B2 (en) 2008-04-23 2011-08-30 Gilead Sciences, Inc. 1′-substituted carba-nucleoside analogs for antiviral treatment
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
CA2748034A1 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Purified 2'-deoxy'2'-fluoro-2'-c-methyl-nucleoside-phosphoramidate prodrugs for the treatment of viral infections
PA8855601A1 (es) 2008-12-23 2010-07-27 Forformidatos de nucleósidos
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
ME01528B (me) * 2009-09-21 2014-04-20 Gilead Sciences Inc POSTUPCI l INTERMEDIJERI ZA PROIZVODNJU 1'-CIJANOKARBANUKLEOZIDIH ANALOGA
US7973013B2 (en) * 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US8455451B2 (en) 2009-09-21 2013-06-04 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
CA2773772C (en) * 2009-09-21 2018-06-26 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
SG184323A1 (en) * 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
JP5937073B2 (ja) 2010-07-19 2016-06-22 ギリード・サイエンシズ・インコーポレーテッド ジアステレオマーとして純粋なホスホルアミデートプロドラッグの調製方法
MX2013000744A (es) 2010-07-22 2013-03-07 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae.
TW201305185A (zh) * 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之２’－氟取代之碳－核苷類似物
JP2013538230A (ja) * 2010-09-20 2013-10-10 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス治療用の２’−フルオロ置換カルバヌクレオシド類似体
ME01980B (me) 2010-11-19 2015-05-20 Gilead Sciences Inc Terapeutske kompozicije koje sadrže rilpivirin hcl i tenofovir dizoproksil fumarat
JP5891241B2 (ja) 2010-12-20 2016-03-22 ギリアード サイエンシーズ， インコーポレイテッド Ｈｃｖを処置するための組合せ
AR088441A1 (es) * 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
MX354958B (es) 2011-09-16 2018-03-27 Gilead Pharmasset Llc Metodos para el tratamiento de vhc.
AR089650A1 (es) 2011-10-14 2014-09-10 Idenix Pharmaceuticals Inc Fosfatos 3,5-ciclicos sustituidos de compuestos de nucleotido de purina y composiciones farmaceuticas para el tratamiento de infecciones virales
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EA201791916A1 (ru) * 2012-03-13 2018-07-31 Джилид Сайэнс, Инк. 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
AR092959A1 (es) 2012-10-17 2015-05-06 Merck Sharp & Dohme Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales
WO2014059901A1 (en) * 2012-10-17 2014-04-24 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases
EP2909210A4 (en) 2012-10-17 2016-04-06 Merck Sharp & Dohme 2'-DISUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR THE USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
RU2015123641A (ru) 2012-11-19 2017-01-10 Мерк Шарп И Доум Корп. 2-алкинилзамещенные производные нуклеозидов, предназначенные для лечения вирусных заболеваний
PL2950786T3 (pl) 2013-01-31 2020-05-18 Gilead Pharmasset Llc Formulacja skojarzona dwóch związków przeciwwirusowych
WO2014204831A1 (en) 2013-06-18 2014-12-24 Merck Sharp & Dohme Corp. Cyclic phosphonate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EP3083654A1 (en) 2013-12-18 2016-10-26 Idenix Pharmaceuticals LLC 4'-or nucleosides for the treatment of hcv
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
WO2016023522A2 (en) 2014-08-15 2016-02-18 Merck Sharp & Dohme Corp. Substituted phosphoramidate compounds and uses thereof
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
TWI687432B (zh) 2014-10-29 2020-03-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
HRP20211456T1 (hr) 2014-12-26 2021-12-24 Emory University Protuvirusni derivati n4-hidroksicitidina
US10618926B2 (en) 2015-04-02 2020-04-14 Merck Sharp & Dohme Process for making phosphoramidate protected nucleoside compounds
CN104945437B (zh) * 2015-05-19 2017-03-01 广州诺威生物技术有限公司 一种嘧啶类新化合物
MA52371A (fr) 2015-09-16 2021-09-22 Gilead Sciences Inc Méthodes de traitement d'infections dues aux coronaviridae
TWI740910B (zh) * 2016-03-09 2021-10-01 美商艾洛斯生物製藥公司 非環抗病毒劑
EP4321513A2 (en) 2016-03-28 2024-02-14 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
CN106083962B (zh) * 2016-06-08 2018-12-18 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
JP7051804B2 (ja) * 2016-07-14 2022-04-11 エフ．ホフマン－ラ ロシュ アーゲー 感染症の治療のための６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物と６，７－ジヒドロ－４Ｈ－トリアゾロ［１，５－ａ］ピラジン化合物
WO2018031818A2 (en) * 2016-08-12 2018-02-15 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CA3056072C (en) 2017-03-14 2022-08-23 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
CN110636884B (zh) 2017-05-01 2022-10-04 吉利德科学公司 新结晶形式
WO2019014247A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS
US11331331B2 (en) 2017-12-07 2022-05-17 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN111788204B (zh) 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
SG11202108283QA (en) * 2019-02-07 2021-08-30 Beigene Ltd Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist
AU2020267486A1 (en) 2019-05-09 2021-11-11 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as STING modulators
AU2021214911A1 (en) 2020-01-27 2022-07-21 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI777411B (zh) 2020-02-18 2022-09-11 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
TW202315607A (zh) 2020-02-18 2023-04-16 美商基利科學股份有限公司 抗病毒化合物
CA3169340A1 (en) 2020-03-12 2021-09-16 Pavel R. Badalov Methods of preparing 1'-cyano nucleosides
AU2021251689A1 (en) 2020-04-06 2022-11-17 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
JP2023528810A (ja) 2020-05-29 2023-07-06 ギリアード サイエンシーズ， インコーポレイテッド レムデシビル治療方法
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
EP4204421A2 (en) 2020-08-27 2023-07-05 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
WO2022219636A1 (en) * 2021-04-14 2022-10-20 Yeda Research And Development Co. Ltd. Anti-viral and anti-tumoral compounds, and uses thereof
CA3216162A1 (en) 2021-04-16 2022-10-20 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
CN117396490A (zh) * 2021-05-14 2024-01-12 Bm医药咨询有限公司 用于预防和治疗病毒感染的双环杂环化合物
US20230295172A1 (en) 2022-03-02 2023-09-21 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
DE69129650T2 (de) 1990-09-14 1999-03-25 Acad Of Science Czech Republic Wirkstoffvorläufer von Phosphonaten
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
DE19912636A1 (de) 1999-03-20 2000-09-21 Aventis Cropscience Gmbh Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
PL364995A1 (en) 2000-02-18 2004-12-27 Shire Biochem Inc. Method for the treatment or prevention of flavivirus
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
CN1646141B (zh) 2000-10-18 2014-06-25 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
EP1707571B1 (en) 2001-01-22 2011-09-28 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
WO2003026675A1 (en) 2001-09-28 2003-04-03 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
EP1576138B1 (en) 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
NZ554442A (en) 2004-09-14 2011-05-27 Pharmasset Inc Preparation of 2'fluoro-2'-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
AU2005317081A1 (en) * 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
WO2006116557A1 (en) * 2005-04-25 2006-11-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
US8431695B2 (en) 2005-11-02 2013-04-30 Bayer Intellectual Property Gmbh Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
US7842672B2 (en) * 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
US20080261913A1 (en) * 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
EP2124555B1 (en) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
PT2114980E (pt) * 2007-01-12 2012-09-25 Biocryst Pharm Inc Análogos de nucleósidos anti-virais
JP2010522241A (ja) 2007-03-21 2010-07-01 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患、アレルギー性疾患、自己免疫疾患または炎症性疾患として有用な縮合ヘテロ環化合物
AU2008251555B2 (en) 2007-05-10 2012-08-30 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-D] dioxolane compounds for use in the treatment of viral infections and cancer
US8227431B2 (en) * 2008-03-17 2012-07-24 Hetero Drugs Limited Nucleoside derivatives
US8008264B2 (en) 2008-04-23 2011-08-30 Gilead Sciences, Inc. 1′-substituted carba-nucleoside analogs for antiviral treatment
WO2010002877A2 (en) 2008-07-03 2010-01-07 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
CA2773772C (en) * 2009-09-21 2018-06-26 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
ME01528B (me) * 2009-09-21 2014-04-20 Gilead Sciences Inc POSTUPCI l INTERMEDIJERI ZA PROIZVODNJU 1'-CIJANOKARBANUKLEOZIDIH ANALOGA

Also Published As

Publication number Publication date
ME02656B (me) 2017-06-20
AU2018204449B2 (en) 2020-01-23
SG179194A1 (en) 2012-05-30
ECSP12011817A (es) 2013-02-28
AU2016262676B2 (en) 2018-03-29
WO2011035231A1 (en) 2011-03-24
ES2730805T3 (es) 2019-11-12
ES2614651T3 (es) 2017-06-01
AU2010295373A1 (en) 2012-04-26
CR20190103A (es) 2019-09-19
BR122021021135B1 (pt) 2022-08-30
SI2480552T1 (sl) 2017-02-28
IL248110A0 (en) 2016-11-30
PL2480552T3 (pl) 2017-06-30
IL218599A (en) 2016-12-29
AU2010295373B2 (en) 2016-09-29
JP5795766B2 (ja) 2015-10-14
DK2480552T3 (en) 2017-02-20
EP3150608B1 (en) 2019-04-10
CY1118605T1 (el) 2017-07-12
ZA201202175B (en) 2012-11-28
EP2480552B1 (en) 2016-11-09
MX2012003391A (es) 2012-06-27
AU2020202600A1 (en) 2020-05-14
AU2020202600B2 (en) 2021-07-01
KR20180006499A (ko) 2018-01-17
EP2480552A1 (en) 2012-08-01
PE20120995A1 (es) 2012-08-01
IL218599A0 (en) 2012-05-31
KR20120102605A (ko) 2012-09-18
PE20160217A1 (es) 2016-05-18
JP2015187126A (ja) 2015-10-29
LT2480552T (lt) 2017-02-10
AP2012006189A0 (en) 2012-04-30
CL2012000707A1 (es) 2012-08-31
UA110466C2 (ru) 2016-01-12
HUE032252T2 (en) 2017-09-28
JP2017075146A (ja) 2017-04-20
EA201200525A1 (ru) 2012-09-28
MX352646B (es) 2017-12-04
JP6033362B2 (ja) 2016-11-30
RS55699B1 (sr) 2017-07-31
AU2016262676A1 (en) 2016-12-08
CA2773772A1 (en) 2011-03-24
HRP20170197T1 (hr) 2017-04-07
JP2013505265A (ja) 2013-02-14
SMT201700091B (it) 2017-03-08
CA2773772C (en) 2018-06-26
KR101818779B1 (ko) 2018-01-15
CR20120186A (es) 2012-07-04
BR112012006261A2 (pt) 2020-08-18
CN102596958A (zh) 2012-07-18
BR122021012877B1 (pt) 2021-10-19
NZ599402A (en) 2014-02-28
PT2480552T (pt) 2017-02-14
EP3150608A1 (en) 2017-04-05
AU2018204449A1 (en) 2018-07-12

Similar Documents

Publication Publication Date Title
PE20210668A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro antivirales
PE20230684A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
UY38483A (es) Heterociclos funcionalizados como agentes antivirales
CL2008003431A1 (es) Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih.
EA201791776A1 (ru) Замещенные циклофаны для использования при лечении инфекции вгс
CO6430431A2 (es) Inhibidores del virus de la hepatitis c
CO6571891A2 (es) Inhibidores del virus de la hepatitis c.
CL2011002830A1 (es) Compuestos derivados de haloalquil heteroaril benzamidas; composicion farmaceutica uso de la composicion en el tratamiento de una infeccion viral, tal como el virus de la hepatitis b y c.
MA37712B1 (fr) Inhibiteurs macrocycliques de virus flaviviridae
GT200500221A (es) Inhibidores de la arn polimerasa dependientes de arn del virus de la hepatitis c composiciones y tratamientos que los usan.
UY28192A1 (es) Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan.
PE20151318A1 (es) Analogos de 2'-cloro nucleosido para infeccion por vhc
BR112015014457A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
CR20130560A (es) Compuestos de bezotiazol y su uso farmacéutico
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
UY28581A1 (es) Compuestos nucleosidicos para el tratamiento de infecciones virales
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BRPI1004894A8 (pt) composto antiviral e composição farmacêutica compreendendo dito composto
UY33097A (es) DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS
ECSP10010210A (es) Compuestos nucleósidos antivirales
EA201990628A1 (ru) 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний
BR112014019584A8 (pt) Composto da fórmula (i), sua forma tautomérica, seu isômero, ou seu sal farmaceuticamente aceitável, composição farmacêutica, método de inibição da replicação de um vírus contendo rna, método de tratamento ou prevenção de infecção causada por um vírus contendo rna, e, método de tratamento de infecção por hepatite c